Literature DB >> 32065790

How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?

Hailey J James1,2, Courtney Harold Van Houtven2,3, Steven Lippmann2, James R Burke4, Megan Shepherd-Banigan2,3, Emmanuelle Belanger5,6, Terrie Fox Wetle6, Brenda L Plassman4,7.   

Abstract

BACKGROUND: Amyloid-β PET scans will likely become an integral part of the diagnostic evaluation for Alzheimer's disease if Medicare approves reimbursement for the scans. However, little is known about patients' and their care partners' interpretation of scan results.
OBJECTIVE: This study seeks to understand how accurately patients with mild cognitive impairment (MCI) or dementia and their care partners report results of amyloid-β PET scans and factors related to correct reporting.
METHODS: A mixed-methods approach was used to analyze survey data from 1,845 patient-care partner dyads and responses to open-ended questions about interpretation of scan results from a sub-sample of 200 dyads.
RESULTS: Eighty-three percent of patients and 85% of care partners correctly reported amyloid-β PET scan results. Patients' higher cognitive function was associated with a small but significant decrease in the predicted probability of not only patients accurately reporting scan results (ME: -0.004, 95% CI: -0.007, -0.000), but also care partners accurately reporting scan results (ME: -0.006, 95% CI: -0.007, -0.001), as well as decreased concordance between patient and care partner reports (ME: -0.004, 95% CI: -0.007, -0.001). Content analysis of open-ended responses found that participants who reported the scan results incorrectly exhibited more confusion about diagnostic terminology than those who correctly reported the scan results.
CONCLUSION: Overall, patients with MCI or dementia showed high rates of accurate reporting of amyloid-β PET scan results. However, responses to questions about the meaning of the scan results highlight the need for improved provider communication, including providing written explanations and better prognostic information.

Entities:  

Keywords:  Alzheimer’s disease; amyloid PET; caregivers; dementia; mild cognitive zzm321990impairment

Mesh:

Substances:

Year:  2020        PMID: 32065790      PMCID: PMC7183243          DOI: 10.3233/JAD-190922

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  23 in total

1.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.

Authors:  Gil D Rabinovici; Constantine Gatsonis; Charles Apgar; Kiran Chaudhary; Ilana Gareen; Lucy Hanna; James Hendrix; Bruce E Hillner; Cynthia Olson; Orit H Lesman-Segev; Justin Romanoff; Barry A Siegel; Rachel A Whitmer; Maria C Carrillo
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

2.  Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

Authors:  David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

3.  Impact of molecular imaging on the diagnostic process in a memory clinic.

Authors:  Rik Ossenkoppele; Niels D Prins; Yolande A L Pijnenburg; Afina W Lemstra; Wiesje M van der Flier; Sofie F Adriaanse; Albert D Windhorst; Ron L H Handels; Claire A G Wolfs; Pauline Aalten; Frans R J Verhey; Marcel M Verbeek; Mark A van Buchem; Otto S Hoekstra; Adriaan A Lammertsma; Philip Scheltens; Bart N M van Berckel
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

4.  Practical utility of amyloid and FDG-PET in an academic dementia center.

Authors:  Pascual Sánchez-Juan; Pia M Ghosh; Jayne Hagen; Benno Gesierich; Maya Henry; Lea T Grinberg; James P O'Neil; Mustafa Janabi; Eric J Huang; John Q Trojanowski; Harry V Vinters; Marilu Gorno-Tempini; William W Seeley; Adam L Boxer; Howard J Rosen; Joel H Kramer; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Neurology       Date:  2013-12-18       Impact factor: 9.910

5.  Development and Initial Validation of the Caregiver Perceptions About Communication With Clinical Team Members (CAPACITY) Measure.

Authors:  Courtney Harold Van Houtven; Katherine E M Miller; Emily C O'Brien; Jennifer L Wolff; Jennifer Lindquist; Margaret Kabat; Margaret Campbell-Kotler; Jennifer Henius; Corrine I Voils
Journal:  Med Care Res Rev       Date:  2017-12-21       Impact factor: 3.929

6.  Brief questions to identify patients with inadequate health literacy.

Authors:  Lisa D Chew; Katharine A Bradley; Edward J Boyko
Journal:  Fam Med       Date:  2004-09       Impact factor: 1.756

7.  Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.

Authors:  Jessica Mozersky; Pamela Sankar; Kristin Harkins; Sara Hachey; Jason Karlawish
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

8.  Decision-making for persons with cognitive impairment and their family caregivers.

Authors:  Lynn Friss Feinberg; Carol J Whitlatch
Journal:  Am J Alzheimers Dis Other Demen       Date:  2002 Jul-Aug       Impact factor: 2.035

9.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Authors:  Sebastian Palmqvist; Henrik Zetterberg; Kaj Blennow; Susanna Vestberg; Ulf Andreasson; David J Brooks; Rikard Owenius; Douglas Hägerström; Per Wollmer; Lennart Minthon; Oskar Hansson
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

10.  Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure.

Authors:  Jennifer H Lingler; J Scott Roberts; Hyejin Kim; Jonna L Morris; Lu Hu; Meghan Mattos; Eric McDade; Oscar L Lopez
Journal:  Alzheimers Dement (Amst)       Date:  2018-05-30
View more
  1 in total

1.  The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations.

Authors:  Rachel L Nosheny; Rebecca Amariglio; Sietske A M Sikkes; Carol Van Hulle; Maria Aparecida Camargos Bicalho; N Maritza Dowling; Sonia Maria Dozzi Brucki; Zahinoor Ismail; Kensaku Kasuga; Elizabeth Kuhn; Katya Numbers; Anna Aaronson; Davide Vito Moretti; Arturo X Pereiro; Gonzalo Sánchez-Benavides; Allis F Sellek Rodríguez; Prabitha Urwyler; Kristina Zawaly
Journal:  Alzheimers Dement (N Y)       Date:  2022-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.